A comprehensive view of Eisai Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Japan’s Eisai Co. reports its injectable Alzheimer’s drug lecanemab, reduced clinical decline in patients with early-stage Alzheimer’s by 27% in late-stage study; Eisai seeks accelerated approval from FDA, with Eisai and Biogen co-promoting the drug

Eisai opens 332,800 square-foot US headquarters in Nutley, New Jersey, with 800 person staff, bringing North American staff count up to 1,982 employees; company expects FDA decision in January on its lecanemab Alzheimer’s drug co-developed with Biogen

FDA accepts Biogen’s BLA seeking accelerated approval of injectable anti-amyloid beta protofibril antibody lecanemab BAN2401 to treat early Alzheimer's disease; Biogen and Eisai collaborated to develop lecanemab

Biogen and Eisai amend existing collaboration on aducanumab, which is marketed in the US as ADUHELM; as of Jan. 1, 2023, Eisai will receive tiered royalty on net sales of ADUHELM, rather than sharing global profits and losses

Eisai and Merck announce approval in Japan for combination of oral Lenvima plus intravenous Keytruda for treatment of renal cell carcinoma

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count